Inactive Instrument

Other languages Protagonist Therapeutics Inc Nasdaq

Equities

US74366E1029

End-of-day quote Nasdaq Other stock markets
- ^PTS	-

05-07	Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-03	Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	04-03
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	03-26
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda	03-18
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study	03-11
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis	03-11
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing	03-04
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing	03-04
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing	03-04
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset	01-31
Protagonist Therapeutics Insider Sold Shares Worth $1,506,000, According to a Recent SEC Filing	12-15
Protagonist Therapeutics Earns $10 Million Milestone Payment in Ulcerative Colitis Trial	12-13
Protagonist Therapeutics, Inc. Announces $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis	12-13
Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib	11-27
Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02
Protagonist Therapeutics, Inc. Announces Achievement of $50 Million Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis	11-01
Protagonist Therapeutics, Inc. Announces Appointment of Daniel N. Swisher, Jr. to Its Board of Director	23-10-30
Protagonist Therapeutics Expects $60 Million Milestone Payments for Psoriasis, Ulcer Drug Development	23-10-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Protagonist Therapeutics Inc Nasdaq

Equities

US74366E1029

Other languages

Filters